Lucid Diagnostics (LUCD) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-40901
Entity Registrant Name	LUCID DIAGNOSTICS INC.
Entity Central Index Key	0001799011
Entity Tax Identification Number	82-5488042
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	One Grand Central Place
Entity Address, Address Line Two	60 E. 42nd Street
Entity Address, Address Line Three	Suite 4600
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10165
City Area Code	(212)
Local Phone Number	949-4319
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	LUCD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		39,108,245

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 26,934	$ 53,656
Accounts receivable	31	200
Prepaid expenses, deposits, and other current assets	2,882	3,447
Total current assets	29,847	57,303
Fixed assets, net	1,499	971
Operating lease right-of-use assets	2,002
Intangible assets, net	3,950
Other assets	1,078	725
Total assets	38,376	58,999
Current liabilities:
Accounts payable	1,102	1,490
Accrued expenses and other current liabilities	1,128	1,113
Operating lease liabilities, current portion	860
Due To: PAVmed Inc. - MSA Fee and operating expenses	6,610	1,657
Total current liabilities	9,700	4,260
Operating lease liabilities, less current portion	1,143
Total liabilities	10,843	4,260
Stockholders’ Equity:
Preferred stock, $0.001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of September 30, 2022 and December 31, 2021
Common stock, $0.001 par value, 100,000,000 shares authorized; 37,016,225 and 34,917,907 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	37	35
Additional paid-in capital	110,643	96,608
Accumulated deficit	(83,147)	(41,904)
Total Stockholders’ Equity	27,533	54,739
Total Liabilities and Stockholders’ Equity	$ 38,376	$ 58,999

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,016,225	34,917,907
Common stock, shares outstanding	37,016,225	34,917,907

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 76	$ 200	$ 265	$ 200
Operating expenses:
Cost of revenue	1,626	144	1,996	144
Sales and marketing	3,930	918	11,121	2,627
General and administrative	5,660	3,458	18,223	7,793
Amortization of acquired intangible assets	505	0	1,144	0
Research and development	2,704	2,190	9,024	5,814
Total operating expenses	14,425	6,710	41,508	16,378
Net loss from operations	(14,349)	(6,510)	(41,243)	(16,178)
Other income (expense):
Interest expense - Senior Unsecured Promissory Note		(447)		(594)
Other income (expense), net		(447)		(594)
Loss before provision for income tax	(14,349)	(6,957)	(41,243)	(16,772)
Provision for income taxes
Net loss	$ (14,349)	$ (6,957)	$ (41,243)	$ (16,772)
Net loss per share - basic and diluted	$ (0.39)	$ (0.49)	$ (1.15)	$ (1.19)
Weighted average common shares outstanding, basic and diluted	36,405,945	14,114,707	35,767,857	14,114,707

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 14	$ 294	$ (13,826)	$ (13,518)
Beginning balance, shares at Dec. 31, 2020	14,114,707
Stock-based compensation - Lucid Diagnostics Inc.		6,045		6,045
Stock-based compensation - PAVmed Inc.		111		111
Net loss			(16,772)	(16,772)
Ending balance, value at Sep. 30, 2021	$ 14	6,450	(30,598)	(24,134)
Ending balance, shares at Sep. 30, 2021	14,114,707
Beginning balance, value at Jun. 30, 2021	$ 14	3,677	(23,641)	(19,950)
Beginning balance, shares at Jun. 30, 2021	14,114,707
Stock-based compensation - Lucid Diagnostics Inc.		2,717		2,717
Stock-based compensation - PAVmed Inc.		56		56
Net loss			(6,957)	(6,957)
Ending balance, value at Sep. 30, 2021	$ 14	6,450	(30,598)	(24,134)
Ending balance, shares at Sep. 30, 2021	14,114,707
Beginning balance, value at Dec. 31, 2021	$ 35	96,608	(41,904)	54,739
Beginning balance, shares at Dec. 31, 2021	34,917,907
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan	$ 1	693		694
Exercise stock options Lucid Diagnostics Inc 2018 Equity Plan, shares	964,716
Stock-based compensation - Lucid Diagnostics Inc.		10,371		10,371
Stock-based compensation - PAVmed Inc.		880		880
Vest - restricted stock awards
Vest restricted stock awards, shares	169,320
APA-RDx - Installment Payment		427		427
APA RDx Installment Payment, shares	199,989
Issuance - Committed Equity Facility, net of deferred financing charges	$ 1	1,766		1,767
Issuance - Committed Equity Facility, net of deferred financing charges, shares	680,263
Purchase - Employee Stock Purchase Plan		109		109
Purchase employee stock purchase plan, shares	84,030
Net loss			(41,243)	(41,243)
CapNostics, LLC transfer		(211)		(211)
Ending balance, value at Sep. 30, 2022	$ 37	110,643	(83,147)	27,533
Ending balance, shares at Sep. 30, 2022	37,016,225
Beginning balance, value at Jun. 30, 2022	$ 36	105,003	(68,798)	36,241
Beginning balance, shares at Jun. 30, 2022	35,994,667
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan		6		6
Exercise stock options Lucid Diagnostics Inc 2018 Equity Plan, shares	5,327
Stock-based compensation - Lucid Diagnostics Inc.		3,280		3,280
Stock-based compensation - PAVmed Inc.		291		291
Vest - restricted stock awards
Vest restricted stock awards, shares	169,320
APA-RDx - Installment Payment		188		188
APA RDx Installment Payment, shares	82,618
Issuance - Committed Equity Facility, net of deferred financing charges	$ 1	1,766		1,767
Issuance - Committed Equity Facility, net of deferred financing charges, shares	680,263
Purchase - Employee Stock Purchase Plan		109		109
Purchase employee stock purchase plan, shares	84,030
Net loss			(14,349)	(14,349)
Ending balance, value at Sep. 30, 2022	$ 37	$ 110,643	$ (83,147)	$ 27,533
Ending balance, shares at Sep. 30, 2022	37,016,225

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (41,243)	$ (16,772)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	1,321	3
Stock-based compensation - Lucid Diagnostics Inc.	10,371	6,045
Stock-based compensation - PAVmed Inc.	880	111
APA-RDx: Issue common stock - settle installment payment	427
Changes in operating assets and liabilities:
Accounts receivable	169	(200)
Prepaid expenses and other current assets	171	(954)
Accounts payable	(388)	781
Accrued expenses and other current liabilities	16	136
Accrued CWRU License Agreement Fee		(223)
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee	2,849	2,688
Due To: PAVmed Inc. - Interest Expense - Senior Unsecured Promissory Note		594
Net cash flows used in operating activities	(25,427)	(7,791)
Cash flows from investing activities
Purchase of equipment	(705)	(38)
Payments - Acquisition	(3,200)
Net cash flows used in investing activities	(3,905)	(38)
Cash flows from financing activities
Proceeds – issue of common stock – Committed Equity Facility	1,807
Proceeds – exercise of stock options	694
Proceeds – issue common stock – Employee Stock Purchase Plan	109
Proceeds – Due To: PAVmed Inc. - working capital cash advances		7,739
Net cash flows provided by financing activities	2,610	7,739
Net increase (decrease) in cash	(26,722)	(90)
Cash, beginning of period	53,656	111
Cash, end of period	$ 26,934	$ 21

Summary Description of the Comp

Summary Description of the Company	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary Description of the Company	Note 1 — Summary Description of the Company Lucid Diagnostics Inc. and Subsidiaries, referred to herein as “Lucid Diagnostics” or the “Company” is comprised of Lucid Diagnostics Inc. and its wholly-owned subsidiaries, inclusive of LucidDx Labs, Inc. and CapNostics LLC. Lucid Diagnostics Inc. is a majority-owned subsidiary of PAVmed Inc., as discussed below. The Company operates in one segment as a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease - “GERD” - which is also known variously as chronic heartburn, acid reflux or simply reflux - who are at risk for developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (“EAC”). Lucid Diagnostics Inc. entered into a patent license agreement with Case Western Reserve University (“CWRU”), captioned the Amended and Restated License Agreement, dated August 23, 2021 (“Amended CWRU License Agreement”). The Amended CWRU License Agreement is a successor to and replaced in its entirety the previous CWRU License Agreement, dated May 12, 2018. The Amended CWRU License Agreement terminates upon the expiration of certain related patents, or on May 12, 2038 in countries where no such patents exist, or upon expiration of any exclusive marketing rights granted by the FDA or other U.S. government agency, whichever comes later. The Amended CWRU License Agreement (as did the predecessor CWRU License Agreement) provides for the exclusive worldwide license of the intellectual property rights for the proprietary technologies of two distinct technology components - the “EsoCheck Cell Collection Device” referred to as “EsoCheck®”; and a panel of proprietary methylated DNA biomarkers, a laboratory developed test (“LDT”), referred to as “EsoGuard®”; and together are collectively referred to as the “EsoGuard Technology”. See the Company’s consolidated financial statements for the year ended December 31, 2021, Note 3, Patent License Agreement - Case Western Reserve University On February 25, 2022, LucidDx Labs, Inc. entered into an asset purchase agreement (“APA”) with ResearchDx, Inc. (“RDx”), an unrelated third-party - “APA-RDx”. Under the APA-RDx, LucidDx Labs Inc. acquired certain assets from RDx to be combined with LucidDx Labs Inc. purchased and leased property and equipment to establish a Company-owned Commercial Lab Improvements Act (“CLIA”) certified, College of American Pathologists (“CAP”) accredited commercial clinical laboratory capable of performing the EsoGuard® Esophageal DNA assay, inclusive of DNA extraction, next generation sequencing (“NGS”) and specimen storage. See Note 6, Asset Purchase Agreement and Management Services Agreement Since its inception, the Company has advanced the proprietary technologies underlying EsoGuard and EsoCheck from the academic research laboratory to commercial diagnostic tests and devices with scalable manufacturing capacity. The Company is presently focused on expanding commercialization across multiple sales channels, including: the communication and education of medical practitioners and clinicians of EsoGuard; and establishing “Lucid Diagnostics Test Centers” for the collection of cell samples using EsoCheck. Recently, the American Gastroenterological Association (“AGA”) and the American College of Gastroenterology (“ACG”) updated its clinical practice guidelines to now support Lucid’s EsoCheck Cell Collection Device and EsoGuard Esophageal DNA Test as an acceptable alternative to endoscopy.Both guidelines expand the addressable market opportunity for these products to now affirmatively include screening women. The AGA updated guideline further expands the target population for the first time to include asymptomatic patients who otherwise present with the certain risk factors. Additionally, the Company is developing expanded clinical evidence to support insurance reimbursement adoption by government and private insurers. Further, the Company is also pursuing development of other products and services, including EsoCure™, an esophageal ablation device. The ability of the Company to generate revenue depends upon the Company’s ability to successfully advance the commercialization of EsoGuard, while also completing its clinical studies to accelerate the adoption of insurance reimbursement. There are no assurances, however, the Company will be able to obtain an adequate level of financial resources required for the long-term commercialization and development of its products and services. Prior to its initial public offering (“IPO”) of its common stock, the operations of the Company were funded by PAVmed Inc., inclusive of providing working capital cash advances and the payment of certain operating expenses on-behalf-of the Company. Additionally, certain operations of Lucid Diagnostics Inc. continue to be managed by personnel of PAVmed Inc., for which Lucid Diagnostics Inc. incurs expense according to the provisions of a Management Services Agreement between Lucid Diagnostics Inc. and PAVmed Inc. See Note 4, Related Party Transactions Due To PAVmed Inc. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company expects to continue to experience recurring losses from operations and will continue to fund its operations with debt and equity financing transactions. Notwithstanding, however, with the cash on-hand as of the date hereof and committed equity sources of financing, the Company expects to be able to fund its operations and meet its financial obligations as they become due for the one year period from the date of the issue of the Company’s unaudited condensed consolidated financial statements, as included herein in this Quarterly Report on Form 10-Q for the period ended September 30, 2022.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Significant Accounting Policies The Company’s significant accounting policies are as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on April 6, 2022, except as otherwise noted herein below. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Lucid Diagnostics Inc. and Subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Lucid Diagnostics Inc. is a majority-owned consolidated subsidiary of PAVmed Inc., which has a majority equity ownership interest and has financial control of Lucid Diagnostics Inc. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2021 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair presentation of the Company’s unaudited condensed consolidated financial information. The consolidated results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2022 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Lucid Diagnostics Inc. and Subsidiaries audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K as filed with the SEC on April 6, 2022. All amounts in the accompanying unaudited condensed consolidated financial statements and these notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts. Reclassifications Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss. Use of Estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of stock-based equity awards and intangible assets. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Leases The Company adopted FASB ASC Topic 842, Leases All significant lease agreements and contractual agreements with embedded lease agreements are accounted for under the provisions of ASC 842, wherein, if the contractual arrangement: involves the use of a distinct identified asset; provides for the right to substantially all the economic benefits from the use of the asset throughout the contractual period; and, provides for the right to direct the use of the asset. A lease agreement is accounted for as either a finance lease (generally with respect real estate) or an operating lease (generally with respect to equipment). Under both a finance lease and an operating lease, the Company recognizes as of the lease commencement date a lease right-of-use (“ROU”) asset and a corresponding lease payment liability. Note 2 — Summary of Significant Accounting Policies - continued A lease ROU asset represents the Company’s right to use an underlying asset for the lease term, and the lease liability represents its contractual obligation to make lease payments. The lease ROU asset is measured at the lease commencement date as the present value of the future lease payments plus initial direct costs incurred. The Company recognizes lease expense of the amortization of the lease ROU asset for an operating lease on a straight-line basis over the lease term; and for financing leases on a straight-line basis unless another basis is more representative of the pattern of economic benefit. The operating ROU asset also includes any lease incentives received for improvements to leased property, when the improvements are lessee owned. For improvements to leased property that are lessor owned, the Company includes amounts the Company incurred for the improvements as ROU assets which are amortized on a straight-line basis over the life of the lease. The lease liability is measured at the lease commencement date with the discount rate generally based on the Company’s incremental borrowing rate (to the extent the lease implicit rate is not known nor determinable), with interest expense recognized using the interest method for financing leases. Certain leases may include options to extend or terminate the agreement. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably certain at lease commencement. As well, an option to terminate is considered unless it is reasonably certain the Company will not exercise the option. The Company elected the practical expedient to not recognize a lease ROU asset and lease payment liability for leases with a term of twelve months or less (“short-term leases”), resulting in the aggregate lease payments being recognized on a straight line basis over the lease term. The Company’s leases with a commencement date prior to January 1, 2022 were short-term leases and therefore did not require recording a ROU asset or lease liability at December 31, 2021. Additionally, the Company elected the practical expedient to not separate lease and non-lease components. Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The key aspects considered by the Company include the following: Contracts Performance obligations Transaction price If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Note 2 — Summary of Significant Accounting Policies When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience Allocate transaction price Practical Expedients

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Note 3 — Revenue from Contracts with Customers EsoGuard Commercialization Agreement The Company entered into the EsoGuard Commercialization Agreement, dated August 1, 2021, with its former commercial laboratory service provider, ResearchDx Inc. (“RDx”), an unrelated third-party. The EsoGuard Commercialization Agreement was on a month-to-month basis and was terminated on February 25, 2022 upon the execution of an asset purchase agreement (“APA”) dated February 25, 2022, between LucidDx Labs Inc., a wholly-owned subsidiary of Lucid Diagnostics Inc., and RDx, with such agreement further discussed in Note 6, Asset Purchase Agreement and Management Services Agreement Revenue Recognized In the three months and nine months ended September 30, 2022, the Company recognized total revenue of $ 76 265 189 100 200 200 Cost of Revenue The cost of revenues principally includes the costs related to the Company’s laboratory operations (excluding estimated costs associated with research activities), the costs related to the EsoCheck cell collection device, cell sample mailing kits and license royalties. In the three months ended September 30, 2022, the cost of revenue was $ 1,626 1,996 369 144 144

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 — Related Party Transactions Case Western Reserve University and Physician Inventors - Amended CWRU License Agreement Case Western Reserve University (“CWRU”) and each of the three physician inventors (“Physician Inventors”) of the intellectual property licensed under the amended and restated patent license agreement with CWRU, dated August 23, 2021 (the “Amended CWRU License Agreement”), each hold a minority equity ownership interest in Lucid Diagnostics Inc. The expenses incurred with respect to the Amended CWRU License Agreement and the three Physician Inventors, as classified in the accompanying consolidated statement of operations for the periods indicated are summarized as follows: Schedule of Incurred Expenses of Minority Shareholders 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of Revenue CWRU – Royalty Fee $ 4 $ 10 $ 13 $ 10 General and Administrative Expense CWRU – License Agreement - Amendment Fee - Milestone III — 10 — 10 Stock-based compensation expense – Physician Inventors’ restricted stock awards 275 273 819 637 Research and Development Expense CWRU License Agreement - reimbursement of patent legal fees — 82 209 195 Fees - Physician Inventors’ consulting agreements 15 8 32 22 Sponsored research agreement 4 — 6 — Stock-based compensation expense – Physician Inventors’ stock options 52 56 151 114 Total Related Party Expenses $ 350 $ 439 $ 1,230 $ 988 PAVmed Inc. - Management Services Agreement The Company’s daily operations of are managed by personnel employed by PAVmed Inc., for which Lucid Diagnostics Inc. incurs a service fee, referred to as the “MSA Fee”, according to the provisions of a Management Services Agreement (“MSA”) with PAVmed Inc. The MSA does not have a termination date, but may be terminated by the Lucid Diagnostics Inc. board of directors. The MSA Fee is charged on a monthly basis and is subject-to periodic adjustment corresponding with changes in the services provided by PAVmed Inc. personnel to the Company, with any such change in the MSA Fee being subject to approval of the boards of directors of each of Lucid Diagnostics Inc. and PAVmed Inc. On August 11, 2022, the respective Company’s boards of directors approved a sixth amendment to the MSA to increase the MSA Fee to $ 550 390 0.70 7,709,836 The MSA Fee expense classification in the unaudited condensed consolidated statement of operations for the periods noted is as follows: Schedule of MSA Fee Expense Classification in Unaudited Condensed Statement of Operations 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of Revenues $ — $ 40 $ — $ 40 Sales & Marketing 330 352 713 971 General & Administrative 891 254 2,175 872 Research & Development 429 224 1,102 627 Total MSA Fee $ 1,650 $ 870 $ 3,990 $ 2,510 Note 4 — Related Party Transactions The classification of the MSA Fee as presented above is based on the PAVmed Inc. classification of employee salary expense. In this regard, PAVmed Inc. classifies employee salary expense as cost-of-revenue for employees engaged in service delivery under the EsoGuard Commercialization Agreement, and sales and marketing expenses for employees performing sales, marketing, and reimbursement activities and functions, general and administrative, and research and development except for those employees who are engaged in product and services engineering development and design and /or clinical trials activities, for which such employee salary is classified as research and development expense. Other Related Party Transactions Lucid Diagnostics Inc. previously entered into a consulting agreement with Stanley N. Lapidus, effective June 2020 with such consulting agreement providing for compensation on a contractual rate per hour for consulting services provided. In July 2021, Mr. Lapidus was appointed as Vice Chairman of the Board of Directors of Lucid Diagnostics Inc. Lucid Diagnostics Inc. recognized general and administrative expense of $ 8 21

Due To PAVmed Inc

Due To PAVmed Inc	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Due To PAVmed Inc	Note 5 — Due To PAVmed Inc The aggregate Due To: PAVmed Inc. for the periods indicated is summarized as follows: Schedule of Senior Unsecured Promissory Note CapNostics, LLC Transfer PAVmed Inc. OBO Payments Employee-Related Costs MSA Fees Total Balance - December 31, 2021 $ — $ 620 $ 1,037 $ — $ 1,657 MSA fees — — — 3,990 3,990 On Behalf Of (OBO) activities — 1,114 — — 1,114 ERC - Payroll & Benefits — — 7,178 — 7,178 CapNostics, LLC transfer 2,105 — — — 2,105 Cash payments to PAVmed Inc. — (1,598 ) (5,496 ) (2,340 ) (9,434 ) Balance - September 30, 2022 $ 2,105 $ 136 $ 2,719 $ 1,650 $ 6,610 CapNostics, LLC On October 5, 2021, PAVmed Subsidiary Corp, a wholly-owned subsidiary of PAVmed Inc., acquired 100% 2.1 100% 2.1 Intangible Assets, net, EsoCure License Agreement with PAVmed Inc. EsoCure has been in development as an esophageal ablation device by PAVmed Inc., with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC, a highly lethal esophageal cancer, and to do so without the need for complex and expensive capital equipment. In April 2022, following the approval from both the Company’s and PAVmed Inc.’s boards of directors, the companies entered into an intercompany license agreement (“EsoCure License Agreement”), pursuant to which the Company was granted the rights to commercialize EsoCure, a technology under development intended for the treatment of dysplastic Barrett’s Esophagus. The EsoCure License Agreement, includes a royalty arrangement whereby the Company will pay PAVmed Inc. a 5% 100 8.0 100

Asset Purchase Agreement and Ma

Asset Purchase Agreement and Management Services Agreement	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Asset Purchase Agreement and Management Services Agreement	Note 6 — Asset Purchase Agreement and Management Services Agreement Asset Purchase Agreement - ResearchDx Inc. Through its wholly-owned subsidiary, LucidDx Labs Inc., the Company entered into an asset purchase agreement (“APA”) dated February 25, 2022, with ResearchDx, Inc. (“RDx”), an unrelated third-party - “APA-RDx”. Under the APA-RDx, LucidDx Labs Inc. acquired certain assets from RDx which were combined with LucidDx Labs Inc. purchased and leased property and equipment to establish a Company-owned CLIA certified, CAP accredited commercial clinical laboratory capable of performing the EsoGuard® Esophageal DNA assay, inclusive of DNA extraction, next generation sequencing (“NGS”) and specimen storage. Prior to February 25, 2022, RDx provided such laboratory services at its owned CLIA-certified, CAP-accredited clinical laboratory. The total purchase price consideration payable under the APA-RDx is a face value of $ 3,200 3,200 Intangible Assets, net. 1,000 3,200 Additionally, the APA-RDx requires the Company to pay a total of $ 3,000 82,618 199,989 188 427 The APA-RDx provides for each of an acceleration and a cancellation of the remaining unpaid installment payments, summarized as follows: ● The payment of the remaining unpaid installment payments will be accelerated as immediately due and payable as of the date the “MSA-RDx” (as such agreement is discussed below) is either terminated by LucidDx Labs Inc. without cause or if it is terminated by mutual agreement between the Company and RDx. ● The payment of the remaining unpaid installment payments will be cancelled if the MSA-RDx is terminated by LucidDx Labs Inc. for cause, defined as the occurrence of any one of: (i) a material breach by RDx which is not cured within thirty days of LucidDx Labs Inc. written notice; (ii) RDx becomes insolvent and /or bankrupt; or (ii) RDx fails to comply with applicable statutes, is barred from participating in federal health care programs, or by action of changes in law or regulation, or by action of judicial interpretation of law, or by judicial civil proceedings decisions. Management Services Agreement - Research Dx Inc LucidDx Labs Inc. and RDx entered into a separate management services agreement (“MSA-RDx”), dated and effective February 25, 2022, with such agreement having a term of three years 150

Prepaid Expenses, Deposits, and

Prepaid Expenses, Deposits, and Other Current Assets	9 Months Ended
	Sep. 30, 2022
Prepaid Expenses Deposits And Other Current Assets
Prepaid Expenses, Deposits, and Other Current Assets	Note 7 — Prepaid Expenses, Deposits, and Other Current Assets Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets September 30, 2022 December 31, 2021 Advanced payments to service providers and suppliers $ 363 $ 260 Prepaid insurance 26 1,578 Deposits 2,389 1,116 EsoCheck cell collection supplies 55 434 EsoGuard mailer supplies 49 59 Total prepaid expenses, deposits and other current assets $ 2,882 $ 3,447

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases
Leases	Note 8 — Leases During the nine months ended September 30, 2022, the Company entered into additional lease agreements that have commenced and are classified as operating leases and short-term leases, including for each of: a commercial clinical laboratory and additional Lucid Test Centers. The Company’s future lease payments as of September 30, 2022, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows: Schedule Of Future Lease Payments Of Operating Lease Liabilities 2022 (remainder of year) $ 246 2023 980 2024 928 2025 24 Total lease payments $ 2,178 Less: imputed interest (175 ) Present value of lease liabilities $ 2,003 Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Schedule Of Cash Flow Supplemental Information Nine Months Ended September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 689 $ — Non-cash investing and financing activities Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,567 $ — Weighted-average remaining lease term - operating leases (in years) 2.24 — Weighted-average discount rate - operating leases 7.875 % — % As of September 30, 2022, the Company’s right-of-use assets from operating leases are $ 2,002 2,003 860 1,143

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Note 9 — Intangible Assets, net Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets Accumulated Amortization Estimated Useful Life September 30, 2022 Defensive technology 60 $ 2,105 Laboratory licenses and certifications and laboratory information management software 24 3,200 Total Intangible assets 5,305 Less Accumulated Amortization (1,355 ) Intangible Assets, net $ 3,950 The defensive technology intangible asset of $ 2.1 0.2 2.1 60 Due To PAVmed Inc. 2.1 As noted in Note 6, Asset Purchase Agreement and Management Services Agreement Amortization expense of the intangible assets discussed above was $ 505 0 1,144 0 Schedule of Future Amortization Expense 2022 (remainder of year) $ 504 2023 2,021 2024 688 2025 421 2026 316 Total $ 3,950

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 10 — Stock-Based Compensation Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (“Lucid Diagnostics Inc. 2018 Equity Plan”) is separate and apart from the PAVmed Inc. 2014 Equity Plan discussed below. The Lucid Diagnostics Inc. 2018 Equity Plan is designed to enable Lucid Diagnostics Inc. to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of Lucid Diagnostics Inc. The types of awards that may be granted under the Lucid Diagnostics Inc. 2018 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics Inc. board of directors. A total of 9,144,000 3,754,051 423,300 50,000 Note 10 — Stock-Based Compensation Lucid Diagnostics Inc. Stock Options Lucid Diagnostics Inc. stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Stock Options Issued and Outstanding Activities Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2021 1,419,242 $ 0.73 7.0 $ 6,665 Granted (1) 2,320,000 $ 3.71 Exercised (964,717 ) $ 0.72 Forfeited (141,436 ) $ 4.33 Outstanding stock options at September 30, 2022 (3) 2,633,089 $ 3.17 8.6 $ 499 Vested and exercisable stock options at September 30, 2022 960,364 $ 2.33 7.2 $ 499 (1) Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan and those granted outside such plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter-end, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics Inc. common stock on each of September 30, 2022 and December 31, 2021 and the exercise price of the underlying Lucid Diagnostics Inc. stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above, are inclusive of 423,300 See Note 4, Related Party Transactions Lucid Diagnostics Inc. Restricted Stock Awards Lucid Diagnostics Inc. restricted stock awards granted under the Lucid Diagnostics Inc. 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2021 1,940,740 $ 12.76 Granted 320,000 4.53 Vested (169,320 ) 13.48 Forfeited — — Unvested restricted stock awards as of September 30, 2022 (1) 2,091,420 $ 11.44 (1) The unvested restricted stock awards presented in the table above, are inclusive of 50,000 On January 7, 2022, 320,000 1.4 PAVmed Inc. 2014 Equity Plan The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the “PAVmed Inc. 2014 Equity Plan”), is separate and apart from the Lucid Diagnostics Inc. 2018 Equity Plan (as such equity plan is discussed above). Note 10 — Stock-Based Compensation Stock-Based Compensation Expense The stock-based compensation expense recognized by the Company for both the Lucid Diagnostics Inc. 2018 Equity Plan and the PAVmed Inc. 2014 Equity Plan, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Lucid Diagnostics Inc 2018 Equity Plan – cost of revenue $ 9 $ — $ 9 $ — Lucid Diagnostics Inc 2018 Equity Plan – sales and marketing expenses 253 — 733 — Lucid Diagnostics Inc 2018 Equity Plan - general and administrative expenses 2,990 2,695 9,504 5,988 Lucid Diagnostics Inc 2018 Equity Plan - research and development expenses 28 21 125 57 PAVmed Inc 2014 Equity Plan - sales and marketing expenses 161 — 497 — PAVmed Inc 2014 Equity Plan - general and administrative expenses 78 — 224 — PAVmed Inc 2014 Equity Plan - research and development expenses 52 56 159 111 Total stock-based compensation expense $ 3,571 $ 2,772 $ 11,251 $ 6,156 The stock-based compensation expense, as presented above, is inclusive of: stock options and restricted stock awards granted under the Lucid Diagnostics Inc. 2018 Equity Plan to employees of PAVmed Inc., the Physician Inventors , and members of the board of directors of Lucid Diagnostics Inc., as well as the stock options granted under the PAVmed Inc. 2014 Equity Plan to the Physician Inventors. As of September 30, 2022, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the Lucid Diagnostics Inc. 2018 Equity Plan and the PAVmed Inc. 2014 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period Unrecognized Expense Weighted Average Remaining Service Period (Years) Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 3,791 2.4 Restricted Stock Awards $ 7,165 0.8 PAVmed Inc. 2014 Equity Plan Stock Options $ 1,618 1.7 Restricted Stock Awards $ 187 1.2 Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $ 1.61 Schedule of Stock-based Compensation Valuation Assumptions Nine Months Ended September 30, 2022 Expected term of stock options (in years) 5.8 Expected stock price volatility 72 % Risk free interest rate 3.2 % Expected dividend yield — % Note 10 — Stock-Based Compensation Lucid Diagnostics, Inc Employee Stock Purchase Plan (“ESPP”) The Lucid Diagnostics Inc Employee Stock Purchase Plan (“Lucid Diagnostics Inc ESPP”), initial six-month stock purchase period was April 1, 2022 to September 30, 2022. A total of 84,030 109 500,000 415,970

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Equity	Note 11 — Stockholders’ Equity Lucid Diagnostics Inc. Common Stock As of September 30, 2022 and December 31, 2021 there were 37,016,225 34,917,907 27,927,190 Committed Equity Facility - March 28, 2022 On March 28, 2022, Lucid Diagnostics, Inc. entered into a committed equity facility with an affiliate of Cantor Fitzgerald (“Cantor”). Under the terms of the committed equity facility, Cantor has committed to purchase up to $ 50 680,263 1,807 In connection with the execution of the agreement for the committed equity facility, the Company paid Cantor $ 1.0

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Note 12 — Net Loss Per Share The “Net loss per share basic and diluted” for the respective periods indicated - is as follows: Schedule of Basic and Fully Diluted Net Loss Per Share 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator Net loss $ (14,349 ) $ (6,957 ) $ (41,243 ) $ (16,772 ) Denominator Weighted average common shares outstanding, basic and diluted 36,405,945 14,114,707 35,767,857 14,114,707 Net loss per share Net loss per share - basic and diluted $ (0.39 ) $ (0.49 ) $ (1.15 ) $ (1.19 ) Basic weighted-average number of shares of common stock outstanding for the periods ended September 30, 2022 and 2021 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows: Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Earnings Per Share September 30, 2022 2021 Stock options 2,633,089 1,399,242 Unvested restricted stock awards 2,091,420 1,806,080 Total 4,724,509 3,205,322

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Lucid Diagnostics Inc. and Subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Lucid Diagnostics Inc. is a majority-owned consolidated subsidiary of PAVmed Inc., which has a majority equity ownership interest and has financial control of Lucid Diagnostics Inc. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2021 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair presentation of the Company’s unaudited condensed consolidated financial information. The consolidated results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2022 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Lucid Diagnostics Inc. and Subsidiaries audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K as filed with the SEC on April 6, 2022. All amounts in the accompanying unaudited condensed consolidated financial statements and these notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts.
Reclassifications	Reclassifications Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss.
Use of Estimates	Use of Estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of stock-based equity awards and intangible assets. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.
Leases	Leases The Company adopted FASB ASC Topic 842, Leases All significant lease agreements and contractual agreements with embedded lease agreements are accounted for under the provisions of ASC 842, wherein, if the contractual arrangement: involves the use of a distinct identified asset; provides for the right to substantially all the economic benefits from the use of the asset throughout the contractual period; and, provides for the right to direct the use of the asset. A lease agreement is accounted for as either a finance lease (generally with respect real estate) or an operating lease (generally with respect to equipment). Under both a finance lease and an operating lease, the Company recognizes as of the lease commencement date a lease right-of-use (“ROU”) asset and a corresponding lease payment liability. Note 2 — Summary of Significant Accounting Policies - continued A lease ROU asset represents the Company’s right to use an underlying asset for the lease term, and the lease liability represents its contractual obligation to make lease payments. The lease ROU asset is measured at the lease commencement date as the present value of the future lease payments plus initial direct costs incurred. The Company recognizes lease expense of the amortization of the lease ROU asset for an operating lease on a straight-line basis over the lease term; and for financing leases on a straight-line basis unless another basis is more representative of the pattern of economic benefit. The operating ROU asset also includes any lease incentives received for improvements to leased property, when the improvements are lessee owned. For improvements to leased property that are lessor owned, the Company includes amounts the Company incurred for the improvements as ROU assets which are amortized on a straight-line basis over the life of the lease. The lease liability is measured at the lease commencement date with the discount rate generally based on the Company’s incremental borrowing rate (to the extent the lease implicit rate is not known nor determinable), with interest expense recognized using the interest method for financing leases. Certain leases may include options to extend or terminate the agreement. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably certain at lease commencement. As well, an option to terminate is considered unless it is reasonably certain the Company will not exercise the option. The Company elected the practical expedient to not recognize a lease ROU asset and lease payment liability for leases with a term of twelve months or less (“short-term leases”), resulting in the aggregate lease payments being recognized on a straight line basis over the lease term. The Company’s leases with a commencement date prior to January 1, 2022 were short-term leases and therefore did not require recording a ROU asset or lease liability at December 31, 2021. Additionally, the Company elected the practical expedient to not separate lease and non-lease components.
Revenue Recognition	Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The key aspects considered by the Company include the following: Contracts Performance obligations Transaction price If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Note 2 — Summary of Significant Accounting Policies When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience Allocate transaction price Practical Expedients

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Schedule of Incurred Expenses of Minority Shareholders	Schedule of Incurred Expenses of Minority Shareholders 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of Revenue CWRU – Royalty Fee $ 4 $ 10 $ 13 $ 10 General and Administrative Expense CWRU – License Agreement - Amendment Fee - Milestone III — 10 — 10 Stock-based compensation expense – Physician Inventors’ restricted stock awards 275 273 819 637 Research and Development Expense CWRU License Agreement - reimbursement of patent legal fees — 82 209 195 Fees - Physician Inventors’ consulting agreements 15 8 32 22 Sponsored research agreement 4 — 6 — Stock-based compensation expense – Physician Inventors’ stock options 52 56 151 114 Total Related Party Expenses $ 350 $ 439 $ 1,230 $ 988
Schedule of MSA Fee Expense Classification in Unaudited Condensed Statement of Operations	Schedule of MSA Fee Expense Classification in Unaudited Condensed Statement of Operations 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of Revenues $ — $ 40 $ — $ 40 Sales & Marketing 330 352 713 971 General & Administrative 891 254 2,175 872 Research & Development 429 224 1,102 627 Total MSA Fee $ 1,650 $ 870 $ 3,990 $ 2,510

Due To PAVmed Inc (Tables)

Due To PAVmed Inc (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Senior Unsecured Promissory Note	The aggregate Due To: PAVmed Inc. for the periods indicated is summarized as follows: Schedule of Senior Unsecured Promissory Note CapNostics, LLC Transfer PAVmed Inc. OBO Payments Employee-Related Costs MSA Fees Total Balance - December 31, 2021 $ — $ 620 $ 1,037 $ — $ 1,657 MSA fees — — — 3,990 3,990 On Behalf Of (OBO) activities — 1,114 — — 1,114 ERC - Payroll & Benefits — — 7,178 — 7,178 CapNostics, LLC transfer 2,105 — — — 2,105 Cash payments to PAVmed Inc. — (1,598 ) (5,496 ) (2,340 ) (9,434 ) Balance - September 30, 2022 $ 2,105 $ 136 $ 2,719 $ 1,650 $ 6,610

Prepaid Expenses, Deposits, a_2

Prepaid Expenses, Deposits, and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Prepaid Expenses Deposits And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets September 30, 2022 December 31, 2021 Advanced payments to service providers and suppliers $ 363 $ 260 Prepaid insurance 26 1,578 Deposits 2,389 1,116 EsoCheck cell collection supplies 55 434 EsoGuard mailer supplies 49 59 Total prepaid expenses, deposits and other current assets $ 2,882 $ 3,447

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
Schedule Of Future Lease Payments Of Operating Lease Liabilities	The Company’s future lease payments as of September 30, 2022, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows: Schedule Of Future Lease Payments Of Operating Lease Liabilities 2022 (remainder of year) $ 246 2023 980 2024 928 2025 24 Total lease payments $ 2,178 Less: imputed interest (175 ) Present value of lease liabilities $ 2,003
Schedule Of Cash Flow Supplemental Information	Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Schedule Of Cash Flow Supplemental Information Nine Months Ended September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 689 $ — Non-cash investing and financing activities Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,567 $ — Weighted-average remaining lease term - operating leases (in years) 2.24 — Weighted-average discount rate - operating leases 7.875 % — %

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets Accumulated Amortization	Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets Accumulated Amortization Estimated Useful Life September 30, 2022 Defensive technology 60 $ 2,105 Laboratory licenses and certifications and laboratory information management software 24 3,200 Total Intangible assets 5,305 Less Accumulated Amortization (1,355 ) Intangible Assets, net $ 3,950
Schedule of Future Amortization Expense	Schedule of Future Amortization Expense 2022 (remainder of year) $ 504 2023 2,021 2024 688 2025 421 2026 316 Total $ 3,950

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Options Issued and Outstanding Activities	Lucid Diagnostics Inc. stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Stock Options Issued and Outstanding Activities Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2021 1,419,242 $ 0.73 7.0 $ 6,665 Granted (1) 2,320,000 $ 3.71 Exercised (964,717 ) $ 0.72 Forfeited (141,436 ) $ 4.33 Outstanding stock options at September 30, 2022 (3) 2,633,089 $ 3.17 8.6 $ 499 Vested and exercisable stock options at September 30, 2022 960,364 $ 2.33 7.2 $ 499 (1) Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan and those granted outside such plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter-end, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics Inc. common stock on each of September 30, 2022 and December 31, 2021 and the exercise price of the underlying Lucid Diagnostics Inc. stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above, are inclusive of 423,300
Schedule of Restricted Stock Award Activity	Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2021 1,940,740 $ 12.76 Granted 320,000 4.53 Vested (169,320 ) 13.48 Forfeited — — Unvested restricted stock awards as of September 30, 2022 (1) 2,091,420 $ 11.44 (1) The unvested restricted stock awards presented in the table above, are inclusive of 50,000
Schedule of Stock-Based Compensation Expense	The stock-based compensation expense recognized by the Company for both the Lucid Diagnostics Inc. 2018 Equity Plan and the PAVmed Inc. 2014 Equity Plan, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Lucid Diagnostics Inc 2018 Equity Plan – cost of revenue $ 9 $ — $ 9 $ — Lucid Diagnostics Inc 2018 Equity Plan – sales and marketing expenses 253 — 733 — Lucid Diagnostics Inc 2018 Equity Plan - general and administrative expenses 2,990 2,695 9,504 5,988 Lucid Diagnostics Inc 2018 Equity Plan - research and development expenses 28 21 125 57 PAVmed Inc 2014 Equity Plan - sales and marketing expenses 161 — 497 — PAVmed Inc 2014 Equity Plan - general and administrative expenses 78 — 224 — PAVmed Inc 2014 Equity Plan - research and development expenses 52 56 159 111 Total stock-based compensation expense $ 3,571 $ 2,772 $ 11,251 $ 6,156
Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period	As of September 30, 2022, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the Lucid Diagnostics Inc. 2018 Equity Plan and the PAVmed Inc. 2014 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period Unrecognized Expense Weighted Average Remaining Service Period (Years) Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 3,791 2.4 Restricted Stock Awards $ 7,165 0.8 PAVmed Inc. 2014 Equity Plan Stock Options $ 1,618 1.7 Restricted Stock Awards $ 187 1.2
Schedule of Stock-based Compensation Valuation Assumptions	Schedule of Stock-based Compensation Valuation Assumptions Nine Months Ended September 30, 2022 Expected term of stock options (in years) 5.8 Expected stock price volatility 72 % Risk free interest rate 3.2 % Expected dividend yield — %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Fully Diluted Net Loss Per Share	The “Net loss per share basic and diluted” for the respective periods indicated - is as follows: Schedule of Basic and Fully Diluted Net Loss Per Share 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator Net loss $ (14,349 ) $ (6,957 ) $ (41,243 ) $ (16,772 ) Denominator Weighted average common shares outstanding, basic and diluted 36,405,945 14,114,707 35,767,857 14,114,707 Net loss per share Net loss per share - basic and diluted $ (0.39 ) $ (0.49 ) $ (1.15 ) $ (1.19 )
Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Earnings Per Share	Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Earnings Per Share September 30, 2022 2021 Stock options 2,633,089 1,399,242 Unvested restricted stock awards 2,091,420 1,806,080 Total 4,724,509 3,205,322

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Details Narrative) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended		9 Months Ended
	Feb. 25, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 76		$ 265
Cost of Revenue		1,626		1,996
Cost of revenue		$ 1,626	$ 144	1,996	$ 144
EsoGuard Commercialization Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax			200	189	200
Payment for fixed monthly fee				$ 100
Cost of Revenue	$ 369
Cost of revenue			$ 144		$ 144

Schedule of Incurred Expenses o

Schedule of Incurred Expenses of Minority Shareholders (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total Related Party Expenses	$ 350	$ 439	$ 1,230	$ 988
Royalty [Member]
CWRU – Royalty Fee	4	10	13	10
General and Administrative Expense [Member]
CWRU – License Agreement - Amendment Fee - Milestone III		10		10
Stock-based compensation expense – Physician Inventors’ stock options	275	273	819	637
Research and Development Expense [Member]
Stock-based compensation expense – Physician Inventors’ stock options	52	56	151	114
CWRU License Agreement - reimbursement of patent legal fees		82	209	195
Fees - Physician Inventors’ consulting agreements	15	8	32	22
Sponsored research agreement	$ 4		$ 6

Schedule of MSA Fee Expense Cla

Schedule of MSA Fee Expense Classification in Unaudited Condensed Statement of Operations (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Related Party Transaction [Line Items]
Sales & Marketing		$ 3,930	$ 918	$ 11,121	$ 2,627
General & Administrative		5,660	3,458	18,223	7,793
Research & Development		2,704	2,190	9,024	5,814
Pavmed Inc [Member]
Related Party Transaction [Line Items]
Total MSA Fee	$ 390
Pavmed Inc [Member] | Management Services Agreement [Member]
Related Party Transaction [Line Items]
Cost of Revenues			40		40
Sales & Marketing		330	352	713	971
General & Administrative		891	254	2,175	872
Research & Development		429	224	1,102	627
Total MSA Fee		$ 1,650	$ 870	$ 3,990	$ 2,510

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended
	Jul. 02, 2022	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Related Party Transaction [Line Items]
Floor price per share			$ 0.70		$ 0.70
Selling, General and Administrative Expense				$ 8		$ 21
Management Services Agreement [Member]
Related Party Transaction [Line Items]
Number of shares issued					7,709,836
Pavmed Inc [Member]
Related Party Transaction [Line Items]
MSA Fee		$ 390
Pavmed Inc [Member] | Management Services Agreement [Member]
Related Party Transaction [Line Items]
MSA Fee			$ 1,650	$ 870	$ 3,990	$ 2,510
Pavmed Inc [Member] | Maximum [Member]
Related Party Transaction [Line Items]
MSA Fee	$ 550

Schedule of Senior Unsecured Pr

Schedule of Senior Unsecured Promissory Note (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Short-Term Debt [Line Items]
Balance - December 31, 2021	$ 1,657
MSA fees	3,990
On Behalf Of (OBO) activities	1,114
ERC - Payroll & Benefits	7,178
CapNostics, LLC transfer	2,105
Cash payments to PAVmed Inc.	(9,434)
Balance - September 30, 2022	6,610
Cap Nostics LLC Transfer [Member]
Short-Term Debt [Line Items]
Balance - December 31, 2021
MSA fees
On Behalf Of (OBO) activities
ERC - Payroll & Benefits
CapNostics, LLC transfer	2,105
Cash payments to PAVmed Inc.
Balance - September 30, 2022	2,105
OBO Payments [Member]
Short-Term Debt [Line Items]
Balance - December 31, 2021	620
MSA fees
On Behalf Of (OBO) activities	1,114
ERC - Payroll & Benefits
CapNostics, LLC transfer
Cash payments to PAVmed Inc.	(1,598)
Balance - September 30, 2022	136
Employee Related Costs [Member]
Short-Term Debt [Line Items]
Balance - December 31, 2021	1,037
MSA fees
On Behalf Of (OBO) activities
ERC - Payroll & Benefits	7,178
CapNostics, LLC transfer
Cash payments to PAVmed Inc.	(5,496)
Balance - September 30, 2022	2,719
MSA Fees [Member]
Short-Term Debt [Line Items]
Balance - December 31, 2021
MSA fees	3,990
On Behalf Of (OBO) activities
ERC - Payroll & Benefits
CapNostics, LLC transfer
Cash payments to PAVmed Inc.	(2,340)
Balance - September 30, 2022	$ 1,650

Due To PAVmed Inc (Details Narr

Due To PAVmed Inc (Details Narrative) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Apr. 01, 2022	Oct. 05, 2021
Purchase Obligation		$ 2.1	$ 2.1
Royalty percentage	5%
Cost of Goods and Services Sold	$ 100
Royalty percentage on annual sales	8%
Cost of goods and services sold annualy	$ 100
Pavmed Inc [Member]
Equity Method Investment, Ownership Percentage			100%
Cap Nostics LLC [Member]
Equity Method Investment, Ownership Percentage		100%

Asset Purchase Agreement and _2

Asset Purchase Agreement and Management Services Agreement (Details Narrative) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Feb. 25, 2022	Sep. 30, 2022	Sep. 30, 2022
Management Services Agreement [Member]
Asset Acquisition [Line Items]
Issuance of shares of common stock			7,709,836
Agreement term	3 years
Professional Fees	$ 150
Research DX Inc [Member] | Purchase Asset Agreement [Member]
Asset Acquisition [Line Items]
Asset Acquisition, Price of Acquisition, Expected	3,200
Intangible assets	$ 3,200
Payments to Acquire Productive Assets		$ 1,000	$ 3,200
Installment payments			$ 3,000
Issuance of shares of common stock		82,618	199,989
Purchase price consideration estimated fair value		$ 188	$ 427

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expenses Deposits And Other Current Assets
Advanced payments to service providers and suppliers	$ 363	$ 260
Prepaid insurance	26	1,578
Deposits	2,389	1,116
EsoCheck cell collection supplies	55	434
EsoGuard mailer supplies	49	59
Total prepaid expenses, deposits and other current assets	$ 2,882	$ 3,447

Schedule Of Future Lease Paymen

Schedule Of Future Lease Payments Of Operating Lease Liabilities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Leases
2022 (remainder of year)	$ 246
2023	980
2024	928
2025	24
Total lease payments	2,178
Less: imputed interest	(175)
Present value of lease liabilities	$ 2,003

Schedule Of Cash Flow Supplemen

Schedule Of Cash Flow Supplemental Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Leases
Operating cash flows from operating leases	$ 689
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 2,567
Weighted-average remaining lease term - operating leases (in years)	2 years 2 months 26 days
Weighted-average discount rate - operating leases	7.875%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases
Operating lease right of use asset	$ 2,002
Operating lease obligations	2,003
Operating Lease, Liability, Current	860
Operating Lease, Liability, Noncurrent	$ 1,143

Schedule of Intangible Assets A

Schedule of Intangible Assets Accumulated Amortization (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Impairment Effects on Earnings Per Share [Line Items]
Total Intangible assets	$ 5,305
Less Accumulated Amortization	(1,355)
Total Intangible Assets, net	$ 3,950
Defensive Technology [Member]
Impairment Effects on Earnings Per Share [Line Items]
Finite-Lived Intangible Asset, Useful Life	60 months
Total Intangible assets	$ 2,105
Laboratory Information Management Software [Member]
Impairment Effects on Earnings Per Share [Line Items]
Finite-Lived Intangible Asset, Useful Life	24 months
Total Intangible assets	$ 3,200

Schedule of Future Amortization

Schedule of Future Amortization Expense (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022 (remainder of year)	$ 504
2023	2,021
2024	688
2025	421
2026	316
Total	$ 3,950

Intangible Assets, net (Details

Intangible Assets, net (Details Narrative) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Oct. 05, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Apr. 02, 2022	Apr. 01, 2022
Impairment Effects on Earnings Per Share [Line Items]
Intangible assets		$ 5,305		$ 5,305
Accumulated amortization		(1,355)		(1,355)
Purchase obligation	$ 2,100						$ 2,100
Amortization expense of intangible assets		505	$ 0	1,144	$ 0
Defensive Technology [Member]
Impairment Effects on Earnings Per Share [Line Items]
Intangible assets		$ 2,105		$ 2,105
Finite lived intangible asset useful life				60 months
Defensive Technology [Member] | Pavmed Inc [Member]
Impairment Effects on Earnings Per Share [Line Items]
Intangible assets						$ 2,100
Accumulated amortization						200
Purchase consideration paid	$ 2,100
Finite lived intangible asset useful life				60 months
Purchase obligation						$ 2,100

Schedule of Stock Options Issue

Schedule of Stock Options Issued and Outstanding Activities (Details) - 2028 Equity Plan [Member]	9 Months Ended		12 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares		Dec. 31, 2021 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options, Outstanding Stock Options Beginning | shares	1,419,242
Weighted Average Exercise Price, Weighted Average Grant Date Fair Value, Outstanding Stock Options Beginning | $ / shares	$ 0.73
Remaining Contractual Term (Years), Outstanding Stock Options Ending	8 years 7 months 6 days	[1]	7 years
Outstanding Stock Options, intrinsic value beginning | $	$ 6,665	[2]
Number of Stock Options, Granted | shares	2,320,000	[3]
Weighted Average Exercise Price, Granted | $ / shares	$ 3.71	[3]
Number of Stock Options, Exercised | shares	(964,717)
Weighted Average Exercise Price, Exercised | $ / shares	$ 0.72
Number of Stock Options, Forfeited | shares	(141,436)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 4.33
Number of Stock Options, Outstanding Stock Options Ending | shares	2,633,089	[1]	1,419,242
Number of Stock Options, Outstanding Stock Options Ending | $ / shares	$ 3.17	[1]	$ 0.73
Outstanding Stock Options, intrinsic value ending | $	$ 499	[1],[2]	$ 6,665	[2]
Number of Stock Options, Vested and exercisable stock options | shares	960,364
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 2.33
Remaining Contractual Term (Years), Vested and Exercisable	7 years 2 months 12 days
Vested and Exercisable Stock Options, intrinsic value | $	$ 499	[2]
[1]The outstanding stock options presented in the table above, are inclusive of 423,300

Schedule of Stock Options Iss_2

Schedule of Stock Options Issued and Outstanding Activities (Details) (Paranthetical) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option grants	423,300	423,300

Schedule of Restricted Stock Aw

Schedule of Restricted Stock Award Activity (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Awards, Outstanding Beginning | shares	1,940,740
Weighted Average Grant Date Fair Value, Outstanding Beginning | $ / shares	$ 12.76
Number of Restricted Stock Awards, Granted | shares	320,000
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 4.53
Number of Restricted Stock Awards, Vested | shares	(169,320)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 13.48
Number of Restricted Stock Awards, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Restricted Stock Awards, Outstanding Ending | shares	2,091,420	[1]
Weighted Average Grant Date Fair Value, Outstanding Ending | $ / shares	$ 11.44	[1]
[1]The unvested restricted stock awards presented in the table above, are inclusive of 50,000

Schedule of Restricted Stock _2

Schedule of Restricted Stock Award Activity (Details) (Paranthetical) - Restricted Stock [Member] - shares		9 Months Ended	12 Months Ended
	Jan. 07, 2022	Sep. 30, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock awards		320,000
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock awards	320,000	50,000	50,000

Schedule of Stock-Based Compens

Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	$ 3,571	$ 2,772	$ 11,251	$ 6,156
2018 Equity Plan [Member] | Cost Of Revenue [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	9		9
2018 Equity Plan [Member] | Selling and Marketing Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	253		733
2018 Equity Plan [Member] | General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	2,990	2,695	9,504	5,988
2018 Equity Plan [Member] | Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	28	21	125	57
PAVmed Inc 2014 EquityPlan [Member] | Selling and Marketing Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	161		497
PAVmed Inc 2014 EquityPlan [Member] | General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	78		224
PAVmed Inc 2014 EquityPlan [Member] | Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	$ 52	$ 56	$ 159	$ 111

Schedule of Unrecognized Compen

Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Stock Options [Member] | 2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 3,791
Weighted Average Remaining Service Period (Years)	2 years 4 months 24 days
Stock Options [Member] | PAVmed Inc 2014 EquityPlan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 1,618
Weighted Average Remaining Service Period (Years)	1 year 8 months 12 days
Restricted Stock [Member] | 2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 7,165
Weighted Average Remaining Service Period (Years)	9 months 18 days
Restricted Stock [Member] | PAVmed Inc 2014 EquityPlan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 187
Weighted Average Remaining Service Period (Years)	1 year 2 months 12 days

Schedule of Stock-based Compe_2

Schedule of Stock-based Compensation Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Expected term of stock options (in years)	5 years 9 months 18 days
Expected stock price volatility	72%
Risk free interest rate	3.20%
Expected dividend yield

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended	12 Months Ended
	Jan. 07, 2022	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds for issuance		$ 109	$ 109
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock awards granted			320,000
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares reserved		9,144,000	9,144,000
Shares available for issue		3,754,051	3,754,051
Stock option grants			423,300	423,300
2018 Equity Plan [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock awards granted	320,000		50,000	50,000
Aggregate grant date fair value	$ 1,400
2018 Equity Plan [Member] | Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average estimated fair value			$ 1.61
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares reserved		500,000	500,000
Shares available for issue		415,970	415,970
Number of common stock purchased			84,030
Proceeds for issuance			$ 109

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($) $ in Thousands		9 Months Ended
	Mar. 28, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares outstanding		37,016,225		34,917,907
Common Stock, Shares, Issued		37,016,225		34,917,907
Proceeds from common stock		$ 1,807
Securities sold under agreements to repurchase	$ 1,000
Commited Equity Facility [Member]
Subsidiary or Equity Method Investee [Line Items]
Common Stock, Shares, Issued		680,263
Proceeds from common stock		$ 1,807
Cantor Fitzgerald [Member] | Commited Equity Facility [Member]
Subsidiary or Equity Method Investee [Line Items]
Stock purchase of shares	$ 50,000
Pavmed Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Majority-interest equity ownership shares		27,927,190

Schedule of Basic and Fully Dil

Schedule of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Net loss	$ (14,349)	$ (6,957)	$ (41,243)	$ (16,772)
Weighted average common shares outstanding, basic and diluted	36,405,945	14,114,707	35,767,857	14,114,707
Net loss per share - basic and diluted	$ (0.39)	$ (0.49)	$ (1.15)	$ (1.19)

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	4,724,509	3,205,322
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	2,633,089	1,399,242
Unvested Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	2,091,420	1,806,080